Key Takeaways
- Presidential Symposium Slot: Moderna stock jumped 12% to $173 on September 21 after Phase 3 melanoma data for its cancer vaccine, intismeran autogene, earned a spot in ESMO’s Presidential Symposium on October 24.
- Vaccine Clearance: The FDA cleared updated Spikevax and mNEXSPIKE shots targeting the JN.1-lineage XFG variant the same day, reinforcing Moderna’s respiratory revenue base heading into flu season.
- Street Lag: Analysts have penciled in a $120 mean target against the $173 close, with 4 buys, 1 outperform, 16 holds, 1 underperform and 1 sell among the 23 covering the stock, a gap of 31% below where shares now sit.
- Coverage Thinning: Price-target coverage fell from 22 analysts a year ago to 18.
Moderna stock (MRNA) trades 31% above the mean target that 23 analysts have penciled in. See how the Street prices oncology upside on TIKR for free →
Why Moderna Stock Jumped 12% on ESMO’s Presidential Symposium News
Moderna (MRNA) stock jumped 12% to $173 on Monday, September 21, after the company said Phase 3 melanoma data for its personalized cancer vaccine will headline a Presidential Symposium slot at the European Society for Medical Oncology Congress on October 24. Three abstracts on the therapy, intismeran autogene, were accepted for the Madrid conference. Only one made the Presidential Symposium, the slot ESMO reserves for data organizers see as capable of changing how oncologists treat patients.
The trial behind it, INTerpath-001, pairs intismeran autogene with Merck’s Keytruda against Keytruda alone in resected melanoma. It is a personalized therapy, built from a patient’s own tumor mutations rather than off a shelf. Moderna President Stephen Hoge previewed the stakes a week earlier at Morgan Stanley 24th Annual Global Healthcare Conference, saying the drug delivered “the first time we’ve ever — anybody has ever achieved that kind of benefit over Keytruda in the adjuvant setting in melanoma.” That framing matters. Keytruda already works well in this setting, so beating it changes the ceiling for what a T-cell priming vaccine can do across other tumors Moderna is testing it in, including lung, bladder and renal cell cancer.
Monday’s jump did not happen in isolation. Moderna stock had already climbed roughly 30% since late August as investors positioned ahead of the ESMO readout, and Monday’s confirmation pushed shares within reach of their 52-week high near $177. Options activity and momentum buying likely amplified the single-day pop on top of the fundamental news.
The move reprices Moderna as an oncology story first and a vaccine maker second, and that shift is what the rest of this article measures against the Street.
Moderna Stock Also Got a Lift From FDA Vaccine Clearances
The same day, the FDA cleared Moderna’s updated 2026-2027 Spikevax and mNEXSPIKE shots targeting the JN.1-lineage XFG variant, the strain regulators picked for this year’s COVID season. That clearance was not the headline, but it removed a piece of uncertainty around Moderna’s base respiratory business right as flu season approaches.
mNEXSPIKE already captured roughly a quarter of the U.S. retail COVID vaccine market in its first season, and the XFG update keeps that franchise current. Layered onto the melanoma news, it gave investors two separate reasons to buy Moderna stock in the same session instead of one.
Moderna Stock’s Mean Target Trails the Rally by 31%
Moderna stock closed at $173 on September 21. The 23 analysts covering the name put a mean target of $120 on it, split between 4 buys, 1 outperform, 16 holds, 1 underperform and 1 sell. That mean sits 31% below where shares now trade, so the median investor recommendation is still hold even after Monday’s pop.
The gap didn’t open overnight. Moderna’s stock price climbed from $28 in June 2025 to $173 by September 21, 2026, roughly six-fold. The mean target rose too, from $48 to $120, but much slower. The Target/Close ratio fell from above 170% in mid-2025 to 69% by September. Targets kept rising. The stock kept outrunning them. Coverage thinned too, from 22 analysts to 18, even as underperforms dropped from 3 to 1.
That’s a Street playing catch-up, not calling the top. October 24 decides whether $120 moves toward $173, or the stock cools first.
Should You Invest in Moderna, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Moderna, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Moderna, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze MRNA stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
